Jan Burger, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the future areas of research that need to be explored in chronic lymphocytic leukemia (CLL) such as why some cells are resistant to treatment. By better understanding what other signaling pathways might be involved in CLL cell proliferation, resistance to current treatments can be prevented and the development of new treatments can take place. This interview took place during the European Research Initiative on CLL (ERIC) International Virtual Meeting 2020.